Free Trial
NYSEAMERICAN:IBIO

iBio Q1 2024 Earnings Report

$0.92 +0.07 (+8.50%)
As of 04/25/2025 04:00 PM Eastern

iBio EPS Results

Actual EPS
-$4.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

iBio Revenue Results

Actual Revenue
$0.05 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

iBio Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, November 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

iBio's Q3 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

iBio Earnings Headlines

iBio announces data from non-human primate PK study of IBIO-600
iBio to transfer listing to Nasdaq from NYSE
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s already performing nearly twice as well as gold this year and looks ready to go much higher. If you wait for the news to hit, you’ll already be too late.
IBio Expands Cardiometabolic And Obesity Program
See More iBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email.

About iBio

iBio (NYSEAMERICAN:IBIO), a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

View iBio Profile

More Earnings Resources from MarketBeat